


Dihydro-β-erythroidine

Cat. No.:	HY-N10497
CAS No.:	23255-54-1
Molecular Formula:	C ₁₆ H ₂₁ NO ₃
Molecular Weight:	275.34
Target:	nAChR
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Dihydro-β-erythroidine is a competitive nicotinic receptor antagonist. Dihydro-β-erythroidine blocks the discriminative stimulus properties of nicotine. Dihydro-β-erythroidine inhibits the anxiolytic effect of nicotine induced ^{[1][2]} .	
In Vivo	Dihydro-β-erythroidine (0.5, 1.6, 5.0 mg/kg; s.c.) blocks the discriminative stimulus properties of nicotine in rats ^[1] . Dihydro-β-erythroidine (100 ng) shows antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus in rats ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	200-250 g male hooded Lister rats ^[1]
	Dosage:	0.5, 1.6, 5.0 mg/kg
	Administration:	S.c.
	Result:	Prevented the development of CTAs (conditioned taste aversion) and blocked the discriminative stimulus effect of nicotine (0.2 or 0.4 mg/kg SC) for 45 min after its administration.

REFERENCES

- [1]. Shoaib M, et al. Antagonism of stimulus properties of nicotine by dihydro-beta-erythroidine (DHbetaE) in rats. *Psychopharmacology (Berl)*. 2000 Apr;149(2):140-6.
- [2]. Cheeta S, et al. Antagonism of the anxiolytic effect of nicotine in the dorsal raphe nucleus by dihydro-beta-erythroidine. *Pharmacol Biochem Behav*. 2001 Dec;70(4):491-6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA